Peptide comparison · Updated September 25, 2026
Tesamorelin and sermorelin both relate to growth-hormone signaling. Their approved uses, research populations and currently marketed products are different.
By the Get Peptide Reviews editorial team · Researched September 25, 2026 · Our review method
The key difference: tesamorelin has an FDA-approved product for a specific condition: excess abdominal fat in adults with HIV-associated lipodystrophy. Sermorelin has a historical Geref record, while current compounded clinic offers are not FDA-approved products. Neither distinction supports treating the two as interchangeable general weight-loss therapies.
Tesamorelin vs sermorelin: the practical differences
| Question | Tesamorelin | Sermorelin |
|---|---|---|
| Regulatory record | Egrifta WR is an approved tesamorelin product with a defined indication and prescribing information. | Historical Geref injection products were discontinued. FDA later determined they were not withdrawn for safety or effectiveness reasons. |
| Evidence discussed here | A randomized 26-week trial in 412 people with HIV and excess abdominal fat. | A short study of GHRH(1–29) hormone responses in ten older men. |
| What was measured? | Visceral adipose tissue and metabolic measures. | Growth hormone and IGF-1 measurements. |
| What must not be assumed? | That results apply to routine weight loss, healthy aging or a compounded copy. | That a hormone change proves better recovery, longer life or the effectiveness of a current clinic’s formulation. |
| What about compounded products? | Compounded drugs are not FDA-approved. Identify the exact product and pharmacy rather than transferring an approved brand’s status to a compounded preparation. | |
Sources 1–5 below. The different sample sizes and outcomes prevent a head-to-head effectiveness conclusion.
What tesamorelin research shows
In the 2007 Falutz trial, 412 participants with HIV and abdominal fat accumulation received tesamorelin or placebo for 26 weeks. Visceral fat decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group [2]. This was a study of a specific population and outcome, not a trial of general weight loss in the public.
The 2025 Egrifta WR label says it is not indicated for weight-loss management and notes that long-term cardiovascular safety has not been established [1]. A follow-up study reported that visceral fat reaccumulated after treatment stopped [6]. Those facts matter when judging durable-benefit claims.
Read our tesamorelin research article for additional background. If you are discussing HIV-associated lipodystrophy, bring the approved-product indication and current label to your treating clinician.
What sermorelin research shows
The Corpas study followed ten older men during short treatment periods and measured hormone responses to GHRH(1–29). It supports an effect on growth hormone and IGF-1 in that setting [3]. It does not establish equivalence to tesamorelin’s visceral-fat trial, long-term health benefits, or results from another route or formulation.
FDA’s Geref withdrawal determination also should be read carefully: “not withdrawn for safety or effectiveness” concerns the historical products [4]. It does not make present-day compounded sermorelin FDA-approved or validate broad anti-aging advertising. Our sermorelin guide separates the mechanism, study findings and consumer questions.
Risks and monitoring are part of the decision
Egrifta WR’s label includes warnings about elevated IGF-1, fluid retention, glucose intolerance or diabetes, and hypersensitivity. It lists contraindications including active malignancy and pregnancy [1]. This is a summary, not the complete prescribing information or a checklist for self-selection.
Do not copy those risks or rates into a claim that sermorelin is safer. The evidence reviewed here does not support a reliable comparative safety ranking. A clinician should assess the exact formulation, your medical history and the monitoring plan. Compounding introduces additional concerns about contamination, potency and product quality [5].
How to compare provider costs without confusing products
A compounded-clinic price is not a quote for branded Egrifta. Separate the drug and formulation first, then compare medication quantity, supply period, consultations, labs and shipping. Avoid choosing a different treatment simply because its advertised monthly number is lower.
For readers already researching a sermorelin consultation, we checked Embody and He & She MD’s public offers on September 25: $99/month advertised by Embody; $229 for a one-month plan at He & She MD, with lower monthly equivalents for longer terms [7–8]. See Embody vs He & She MD for the financial comparison.
Related sermorelin programs
These buttons lead to sermorelin offers. They are not offers for FDA-approved Egrifta and are not a recommendation to substitute one drug for another.
Published monthly offer
Embody sermorelin
$99 / month advertised
Compare the selected formulation, supplied quantity and renewal arrangement.
See Embody sermorelin plansChoice of plan lengths
He & She MD
$229 / one-month plan
Published monthly equivalents fall to $149 with a twelve-month supply purchase.
See He & She MD sermorelinAffiliate disclosure: we may earn a commission if you enroll through a provider button. These are commercial comparisons, not clinical recommendations. How our links work.
Frequently asked comparison questions
Is tesamorelin better than sermorelin for fat loss?
The evidence here does not answer a general head-to-head question. Tesamorelin’s trial and approved indication concern HIV-associated abdominal fat, while the sermorelin-related study discussed here measures hormones in a different population.
Is either one an FDA-approved weight-loss treatment?
Egrifta WR’s label specifically says it is not indicated for weight-loss management. The compounded sermorelin programs described here are not FDA-approved products.
Should they be used together?
This comparison provides no evidence supporting a self-directed combination or stacking plan. Discuss the treatment goal, alternatives and risks with a qualified clinician.
Continue your research
Sources and research notes
Primary sources checked September 25, 2026. Addresses below are provided as plain text so you can identify and check each document.
-
FDA — Egrifta WR prescribing information, March 2025
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf -
Falutz J et al. — Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM, 2007. PMID 18057338
https://pubmed.ncbi.nlm.nih.gov/18057338/ -
Corpas E et al. — GHRH(1–29) study in older men, 1992. PMID 1379256
https://pubmed.ncbi.nlm.nih.gov/1379256/ -
FDA — Geref withdrawal determination, March 2013
https://public-inspection.federalregister.gov/2013-04827.pdf -
FDA — Understanding the Risks of Compounded Drugs
https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs -
Falutz J et al. — Long-term safety and effects of tesamorelin, 2008. PMID 18690162
https://pubmed.ncbi.nlm.nih.gov/18690162/ -
Embody — Sermorelin Therapy, public offer
https://sermorelin.joinem.co/ -
He & She MD — Sermorelin Injectable, public plan table
https://heandshemd.com/longevity/sermorelin/
This is consumer research, not medical advice or a personal treatment recommendation. We did not buy treatment, complete medical intake or test clinical outcomes. No medical-review credential is claimed. Send a documented correction.